Navigation Links
BIDMC scientists receive creativity awards from Prostate Cancer Foundation
Date:4/14/2009

BOSTON Two projects led by scientists at Beth Israel Deaconess Medical Center (BIDMC) have received funding from the Prostate Cancer Foundation (PCF) as part of their 2009 Creativity Awards program, which supports innovative ideas to improve the detection and treatment of prostate cancer.

The one-year awards were made to 10 projects at nine institutions throughout the U.S., with BIDMC the only institution in New England to be funded and the only institution to receive multiple awards.

PCF Creativity Awards were developed to aid the advancement of the world's most imaginative, new research ideas that are not currently funded by any existing government or private sources.

"We were impressed with the unique ideas represented by the applications we received. A rigorous peer review process vetted the 10 selected projects from a field of more than 300 applications representing 105 institutions in 11 countries," said Howard Soule, PhD, PCF executive vice president and chief scientist. "These awards feed our pipeline of compelling ideas to cultivate new solutions for the prostate cancer problem. Promising results will translate into better therapies for patients with advanced prostate cancer."

Towia Libermann, PhD, and Alan Rigby, PhD, will receive the Michael Vinecki Creativity Award for their work studying Ets factor binding sites on DNA, the first step in selecting candidate prostate cancer inhibitors. "We know that in 40 to 60 percent of prostate cancers, Ets factors are what lies behind both the initial disease and its progression," notes Libermann. He and Rigby will use a state-of-the-art computer-aided drug discovery platform developed in the Rigby laboratory to model the structure of these sites, with the ultimate goal of generating drug candidates to block prostate-cancer progression. Libermann is Director of the BIDMC Genomics and Proteomics Center and of the Dana-Farber/Harvard Cancer Center Proteomics Core in BIDMC's Division of Interdisciplinary Medicine and Biotechnology; Rigby is Interim Director of the Program in Drug Discovery and Target Validation in BIDMC's Center for Vascular Biology Research, Division of Molecular and Vascular Biology.

Pier Paolo Pandolfi, MD, PhD, Director of Research for BIDMC's Cancer Center will receive PCF's Dan Fogleberg Creativity Award for his work on cellular senescence. "Cellular senescence is a process whereby cancer cells 'go to sleep irreversibly,'" explains Pandolfi. Building on earlier work which identified a previously unknown form of senescence in prostate cancer cells, Pandolfi will use specialized animal models of prostate cancer to evaluate chemical compounds to achieve senescence in the cancer stem cell population, which is known to be extremely difficult to eradicate.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Biotech company cofounded by BIDMC scientists targets natural killer T-cells
2. Healthcare Data Services (HDS) Announces Contract with Beth Israel Deaconess Physician Organization (BIDPO) and Beth Israel Deaconess Medical Center (BIDMC)
3. BIDMC Dyslexia Research Lab celebrates 25th anniversary
4. Scientists discover way to jumpstart bones healing process
5. Scripps research scientists model 3D structures of proteins that control human clock
6. Scientists Identify Key Gene That Protects Against Leukemia
7. Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium
8. Scientists Now Warn That White Wine Can Lead To Teeth Staining
9. Scientists Uncover New Weapon Against Huntingtons
10. Scientists show how a neuron gets its shape
11. Neuroscientists demonstrate link between brainwave acticity and visual perception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... MN (PRWEB) , ... March 24, 2017 , ... ... back to the military at the same time by providing Prehospital Trauma Life ... Guard. PHTLS is the world’s premier prehospital trauma education developed in cooperation with ...
(Date:3/24/2017)... ... 2017 , ... According to a new study by NCPA Senior Fellow John ... the rules Congress has directed the CBO to follow. The CBO itself previously recognized ... Yet, it estimates a reduction in employer-based coverage due to the GOP reform, which ...
(Date:3/24/2017)... San Diego, Calif. (PRWEB) , ... March 24, ... ... (ADI) has raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden ... demonstrates the instant demand for the product – with nearly 2,000 consumers (and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate ... historical facts, cultural practices, goods, services, and societal issues tend to appreciate and love ... the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... ... 2017 , ... “End Time GPS”: a dauntless and enlightened study of ... GPS” is the creation of published author, Wesley Gerboth, a World War II veteran, ... space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: